{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Secondary+Hyperparathyroidism&page=2",
    "query": {
      "condition": "Secondary Hyperparathyroidism",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Secondary+Hyperparathyroidism&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T03:08:35.368Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01290029",
      "title": "Study to Evaluate Cinacalcet in Children With Chronic Kidney Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Chronic Kidney Disease",
        "Hyperparathyroidism, Secondary",
        "Secondary Hyperparathyroidism"
      ],
      "interventions": [
        {
          "name": "Cinacalcet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "28 Days",
        "maximum_age": "2190 Days",
        "sex": "ALL",
        "summary": "28 Days to 2190 Days"
      },
      "enrollment_count": 14,
      "start_date": "2011-01-25",
      "completion_date": "2015-09-23",
      "has_results": true,
      "last_update_posted_date": "2020-06-17",
      "last_synced_at": "2026-05-22T03:08:35.368Z",
      "location_count": 4,
      "location_summary": "Los Angeles, California • San Francisco, California • Louisville, Kentucky + 1 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Kansas City",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01290029"
    },
    {
      "nct_id": "NCT05543928",
      "title": "Phase 3 Safety and Efficacy Study of CTAP101 Extended-release Capsules in Children With Secondary Hyperparathyroidism",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Kidney Disease stage3",
        "Chronic Kidney Disease stage4",
        "Vitamin d Deficiency",
        "Secondary Hyperparathyroidism"
      ],
      "interventions": [
        {
          "name": "CTAP101",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "OPKO Health, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "8 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "8 Years to 17 Years"
      },
      "enrollment_count": 2,
      "start_date": "2023-01-31",
      "completion_date": "2024-06-19",
      "has_results": true,
      "last_update_posted_date": "2025-07-25",
      "last_synced_at": "2026-05-22T03:08:35.368Z",
      "location_count": 2,
      "location_summary": "Columbus, Ohio • Greenville, South Carolina",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Greenville",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05543928"
    },
    {
      "nct_id": "NCT01134562",
      "title": "Safety, Tolerability and Pharmacokinetics of Etelcalcetide in Hemodialysis Patients With Secondary Hyperparathyroidism",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hyperparathyroidism, Secondary"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Etelcalcetide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "KAI Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 28,
      "start_date": "2010-09-07",
      "completion_date": "2011-04-02",
      "has_results": true,
      "last_update_posted_date": "2018-01-02",
      "last_synced_at": "2026-05-22T03:08:35.368Z",
      "location_count": 3,
      "location_summary": "Cypress, California • Shreveport, Louisiana • Houston, Texas",
      "locations": [
        {
          "city": "Cypress",
          "state": "California"
        },
        {
          "city": "Shreveport",
          "state": "Louisiana"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01134562"
    },
    {
      "nct_id": "NCT00888069",
      "title": "Pharmacokinetics and Safety Pilot Study of Single-Dose Oral and Intravenous CTAP101 in Stage 3 and 4 Chronic Kidney Disease Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Chronic Kidney Disease",
        "Secondary Hyperparathyroidism",
        "Chronic Renal Insufficiency",
        "Chronic Renal Failure"
      ],
      "interventions": [
        {
          "name": "CTAP101 Capsules",
          "type": "DRUG"
        },
        {
          "name": "CTAP101 Injection",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "OPKO IP Holdings II, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 28,
      "start_date": "2009-05",
      "completion_date": "2009-12",
      "has_results": false,
      "last_update_posted_date": "2014-09-30",
      "last_synced_at": "2026-05-22T03:08:35.368Z",
      "location_count": 12,
      "location_summary": "Peoria, Arizona • Evergreen Park, Illinois • Springfield, Massachusetts + 9 more",
      "locations": [
        {
          "city": "Peoria",
          "state": "Arizona"
        },
        {
          "city": "Evergreen Park",
          "state": "Illinois"
        },
        {
          "city": "Springfield",
          "state": "Massachusetts"
        },
        {
          "city": "Brooklyn Center",
          "state": "Minnesota"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00888069"
    },
    {
      "nct_id": "NCT07494045",
      "title": "Pharmacokinetics, Pharmacodynamics, Safety and Tolerability Evaluation of CTAP101 Extended-release Capsules in Pediatric Participants",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "CKD Stage 3",
        "CKD Stage 4",
        "Secondary Hyperparathyroidism",
        "VDI"
      ],
      "interventions": [
        {
          "name": "CTAP101",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "OPKO Health, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Month",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "1 Month to 17 Years"
      },
      "enrollment_count": 40,
      "start_date": "2026-06",
      "completion_date": "2028-08",
      "has_results": false,
      "last_update_posted_date": "2026-03-30",
      "last_synced_at": "2026-05-22T03:08:35.368Z",
      "location_count": 5,
      "location_summary": "Kansas City, Missouri • Columbus, Ohio • Philadelphia, Pennsylvania + 2 more",
      "locations": [
        {
          "city": "Kansas City",
          "state": "Missouri"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Greenville",
          "state": "South Carolina"
        },
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07494045"
    },
    {
      "nct_id": "NCT05880914",
      "title": "Precision Medicine Approaches to Renal Osteodystrophy",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Renal Osteodystrophy",
        "Chronic Kidney Diseases",
        "CKD-MBD",
        "Bone Turnover Rate Disorder",
        "Secondary Hyperparathyroidism"
      ],
      "interventions": [
        {
          "name": "miRNAseq analysis",
          "type": "PROCEDURE"
        },
        {
          "name": "Standard treatment for bone disorder",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "Thomas Nickolas",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2022-12-21",
      "completion_date": "2027-06-30",
      "has_results": false,
      "last_update_posted_date": "2025-06-27",
      "last_synced_at": "2026-05-22T03:08:35.368Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05880914"
    },
    {
      "nct_id": "NCT03043482",
      "title": "A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of VS 105",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Chronic-kidney Disease Stage 5D on Stable Hemodialysis"
      ],
      "interventions": [
        {
          "name": "Single VS-105/placebo to healthy",
          "type": "DRUG"
        },
        {
          "name": "Multiple VS-105/placebo to healthy",
          "type": "DRUG"
        },
        {
          "name": "Multiple VS-105/placebo to HD subjects",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vidasym, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 69,
      "start_date": "2017-01-24",
      "completion_date": "2018-03-31",
      "has_results": false,
      "last_update_posted_date": "2019-10-07",
      "last_synced_at": "2026-05-22T03:08:35.368Z",
      "location_count": 1,
      "location_summary": "Lakewood, Colorado",
      "locations": [
        {
          "city": "Lakewood",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03043482"
    },
    {
      "nct_id": "NCT01704079",
      "title": "Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insufficiency",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Kidney Disease",
        "Hyperparathyroidism, Secondary",
        "Vitamin D Deficiency"
      ],
      "interventions": [
        {
          "name": "CTAP101 30 μg capsules",
          "type": "DRUG"
        },
        {
          "name": "Sugar pill to CTAP101 30 μg capsules",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "OPKO IP Holdings II, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 216,
      "start_date": "2012-11",
      "completion_date": "2014-09",
      "has_results": true,
      "last_update_posted_date": "2025-01-13",
      "last_synced_at": "2026-05-22T03:08:35.368Z",
      "location_count": 1,
      "location_summary": "Bannockburn, Illinois",
      "locations": [
        {
          "city": "Bannockburn",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01704079"
    },
    {
      "nct_id": "NCT03633708",
      "title": "A Trial of Etelcalcetide in Pediatric Participants With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Secondary Hyperparathyroidism",
        "Chronic Kidney Disease"
      ],
      "interventions": [
        {
          "name": "Etelcalcetide",
          "type": "DRUG"
        },
        {
          "name": "Standard of Care",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "0 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "0 Years to 18 Years"
      },
      "enrollment_count": 56,
      "start_date": "2019-04-29",
      "completion_date": "2029-01-31",
      "has_results": false,
      "last_update_posted_date": "2026-02-27",
      "last_synced_at": "2026-05-22T03:08:35.368Z",
      "location_count": 10,
      "location_summary": "Los Angeles, California • Aurora, Colorado • Kansas City, Missouri + 7 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Kansas City",
          "state": "Missouri"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03633708"
    },
    {
      "nct_id": "NCT00415584",
      "title": "Cinacalcet to Treat Hypercalcemia in Renal Transplant Recipients",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Secondary Hyperparathyroidism",
        "Hypercalcemia"
      ],
      "interventions": [
        {
          "name": "Cinacalcet HCl",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Montefiore Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 4,
      "start_date": "2007-02-09",
      "completion_date": "2009-11",
      "has_results": true,
      "last_update_posted_date": "2025-04-29",
      "last_synced_at": "2026-05-22T03:08:35.368Z",
      "location_count": 1,
      "location_summary": "The Bronx, New York",
      "locations": [
        {
          "city": "The Bronx",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00415584"
    }
  ]
}